Dostarlimab was used in rectal cancer at Sloan Kettering
Resuls were amazing just look at the pics in the June NEJM
The cancers disappear,
And when combined with efti results could eclipse efti/Keytruda results.
But Tacti 002 trial indicate efti/Keytruda combo will beat Dostarlimab.
Looks like efti is the key to the next Immuno King
Maybe GSK is making an offer knowing this
Dostarlimab was used in rectal cancer at Sloan Kettering Resuls...
-
- There are more pages in this discussion • 559 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
-0.040(11.9%) |
Mkt cap ! $428.5M | |||
| Open | High | Low | Value | Volume |
| 32.0¢ | 33.0¢ | 28.0¢ | $7.278M | 23.75M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 53192 | 29.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.5¢ | 41048 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| IMM (ASX) Chart |